Casellas F, Gutierrez-Casbas A, Rodriguez C, Gisbert JP, et al. EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-alpha as first- or second-line biologic treatment among patients with ulcerative colitis. Gastroenterol Hepatol 2025 Jul 11:502528. doi: 10.1016/j.gastrohep.2025.502528.
PMID: 40653009